Metopocor (Metoprolol Tartrate)

Metoprolol tartrate blocks β1‑adrenergic receptors in the heart, diminishing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, reduced contractile force, and lower renin release, collectively decreasing cardiac output and systemic blood pressure while also lowering myocardial oxygen demand.

The appropriate dose of Metopocor is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, response to therapy, and any comorbidities. Dosing regimens are not standardized in public literature and should follow the prescribing information provided by the healthcare professional.

Safety data for metoprolol tartrate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician. Breastfeeding mothers should consult their doctor before using the product.

To request Metopocor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metopocor (metoprolol tartrate) is a cardio‑selective β1‑blocker, offering a more targeted effect on heart rate and contractility compared with non‑selective agents such as propranolol. This selectivity generally results in fewer respiratory side effects, making it a preferred option for patients with coexisting pulmonary disease, while still providing effective blood pressure and anti‑anginal control.

Metopocor should be stored at temperatures below 25 °C, in its original packaging, protected from light and moisture. The product must be kept out of reach of children and handled according to standard aseptic techniques for intravenous solutions to maintain sterility until administration.

Metopocor is supplied as an intravenous solution and is administered by slow IV injection or infusion under the supervision of a qualified healthcare professional. The exact rate and duration of administration are determined by the prescriber based on the clinical indication and patient response.

Serious adverse events include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of these conditions, especially during dose initiation or when combined with other medications that affect cardiac conduction.

Metopocor is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block without a pacemaker, cardiogenic shock, and in individuals with uncompensated heart failure. Caution is also advised for patients with severe asthma or chronic obstructive pulmonary disease.